Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Montalescot, A. Hof, F. Lapostolle, J. Silvain, J. Lassen, L. Bolognese, W. Cantor, Á. Cequier, M. Chettibi, S. Goodman, C. Hammett, K. Huber, M. Janzon, B. Merkely, R. Storey, U. Zeymer, O. Stibbe, P. Ecollan, Wim Heutz, E. Swahn, J. Collet, F. Willems, Caroline Baradat, M. Licour, A. Tsatsaris, E. Vicaut, C. Hamm (2014)
Prehospital ticagrelor in ST-segment elevation myocardial infarction.The New England journal of medicine, 371 11
Prourokinase xx/xx (xx) xx/xx (xx) Urokinase xx/xx (xx) xx/xx (xx) Streptokinase xx/xx (xx) xx/xx (xx) Other xx/xx (xx) xx/xx (xx)
S. Husted, J. Giezen (2009)
Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor AntagonistCardiovascular Therapeutics, 27
G. Stone, B. Witzenbichler, G. Guagliumi, J. Peruga, B. Brodie, Dariusz Dudek, Ran Kornowski, Franz Hartmann, B. Gersh, S. Pocock, G. Dangas, S. Wong, Ajay Kirtane, H. Parise, R. Mehran (2008)
Bivalirudin during primary PCI in acute myocardial infarction.The New England journal of medicine, 358 21
Zhengming Chen, Lixin Jiang, Yiping Chen, J. Xie, H. Pan, R. Peto, R. Collins, Lisheng Liu, Commit (2005)
Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trialThe Lancet, 366
D. Alexopoulos, A. Perperis, I. Koniari, H. Karvounis, S. Patsilinakos, A. Ziakas, N. Barampoutis, Theofilos Panagiotidis, Karolina Akinosoglou, G. Hahalis, I. Xanthopoulou (2015)
Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysisJournal of Thrombosis and Thrombolysis, 40
B. Ibáñez, Stefan James, S. Agewall, M. Antunes, C. Bucciarelli-Ducci, H. Bueno, A. Caforio, F. Crea, J. Goudevenos, S. Halvorsen, G. Hindricks, A. Kastrati, M. Lenzen, E. Prescott, M. Roffi, M. Valgimigli, C. Varenhorst, P. Vranckx, Petr Widimsky (2018)
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).European heart journal, 39 2
P. Dehghani, A. Lavoie, S. Lavi, J. Crawford, S. Harenberg, Rodney Zimmermann, Jeff Booker, S. Kelly, W. Cantor, S. Mehta, A. Bagai, S. Goodman, A. Cheema (2017)
Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.American heart journal, 192
A. Vora, D. Holmes, I. Rokos, M. Roe, C. Granger, W. French, E. Antman, T. Henry, L. Thomas, E. Bates, Tracy Wang (2015)
Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry.JAMA internal medicine, 175 2
P. Dalgaard (2010)
R Development Core Team (2010): R: A language and environment for statistical computing
S. Husted, H. Emanuelsson, S. Heptinstall, P. Sandset, M. Wickens, G. Peters (2006)
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.European heart journal, 27 9
O. Berwanger, J. Nicolau, A. Carvalho, Lixin Jiang, S. Goodman, S. Nicholls, A. Parkhomenko, O. Averkov, C. Tajer, G. Málaga, J. Saraiva, F. Fonseca, H. Guimarães, P. Silva, L. Damiani, D. Paisani, C. Lasagno, Carolina Candido, Nanci Valeis, D. Moia, L. Piegas, C. Granger, H. White, R. Lopes (2018)
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST‐elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trialAmerican Heart Journal, 202
S. James, A. Åkerblom, C. Cannon, H. Emanuelsson, S. Husted, H. Katus, A. Skene, P. Steg, R. Storey, R. Harrington, R. Becker, L. Wallentin (2009)
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.American heart journal, 157 4
P. Bacchetti, J. Leung (2002)
Sample size calculations in clinical research.Anesthesiology, 97 4
P. O'Gara, F. Kushner, D. Ascheim, D. Casey, M. Chung, J. Lemos, S. Ettinger, J. Fang, F. Fesmire, B. Franklin, C. Granger, H. Krumholz, Jane Linderbaum, D. Morrow, L. Newby, J. Ornato, N. Ou, M. Radford, J. Tamis-Holland, C. Tommaso, C. Tracy, Y. Woo, David Zhao (2013)
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Journal of the American College of Cardiology, 61 4
S. Buuren, K. Groothuis-Oudshoorn (2011)
MICE: Multivariate Imputation by Chained Equations in RJournal of Statistical Software, 45
L. Guimarães, P. Généreux, Diego Silveira, A. Pesaro, F. Falcão, Bruno Barbosa, Cristiano Souza, F. Fonseca, C. Alves, A. Carvalho, G. Stone, A. Caixeta (2017)
P2Y12 receptor inhibition with prasugrel and ticagrelor in STEMI patients after fibrinolytic therapy: Analysis from the SAMPA randomized trial.International journal of cardiology, 230
R. Mehran, S. Rao, Deepak Bhatt, C. Gibson, A. Caixeta, J. Eikelboom, S. Kaul, S. Wiviott, V. Menon, E. Nikolsky, V. Serebruany, M. Valgimigli, P. Vranckx, D. Taggart, J. Sabik, D. Cutlip, M. Krucoff, E. Ohman, P. Steg, H. White (2011)
Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research ConsortiumCirculation, 123
L. Wallentin, R. Becker, A. Budaj, C. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K. Mahaffey, B. Scirica, A. Skene, P. Steg, R. Storey, R. Harrington, A. Freij, M. Thorsén (2009)
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 361 11
M. Sabatine, C. Cannon, C. Gibson, J. López-Sendón, G. Montalescot, P. Théroux, M. Claeys, F. Cools, K. Hill, A. Skene, C. Mccabe, E. Braunwald (2005)
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.The New England journal of medicine, 352 12
P. Grambsch, T. Therneau (1994)
Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 81
Reteplase xx(xx-xx) xx(xx-xx)
M. Huque, Mohamed Alosh (2008)
A flexible fixed-sequence testing method for hierarchically ordered correlated multiple endpoints in clinical trialsJournal of Statistical Planning and Inference, 138
S. Gandhi, B. Zile, M. Tan, J. Saranu, C. Bucci, A. Yan, P. Robertson, M. Quantz, E. Letovsky, J. Tanguay, J. Dery, D. Fitchett, M. Madan, W. Cantor, M. Heffernan, M. Natarajan, G. Wong, R. Welsh, S. Goodman (2014)
Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective.The Canadian journal of cardiology, 30 12
F. Werf (1999)
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trialThe Lancet, 354
W. Cantor, D. Fitchett, B. Borgundvaag, J. Ducas, M. Heffernan, E. Cohen, L. Morrison, A. Langer, V. Džavík, S. Mehta, C. Lazzam, Brian Schwartz, A. Casanova, S. Goodman (2009)
Routine early angioplasty after fibrinolysis for acute myocardial infarction.The New England journal of medicine, 360 26
P. Steg, S. James, R. Harrington, D. Ardissino, Richard Becker, Christopher Cannon, H. Emanuelsson, A. Finkelstein, S. Husted, H. Katus, J. Kilhamn, Sylvia Olofsson, Robert Storey, W. Weaver, L. Wallentin (2010)
Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup AnalysisCirculation, 122
Time from fibrinolytic administration to randomization, median (IQR)
Key PointsQuestionIn patients with ST-elevation myocardial infarction treated with fibrinolytic therapy, is ticagrelor noninferior to clopidogrel with respect to thrombolysis in myocardial infarction major bleeding at 30 days? FindingsIn this randomized clinical trial of 3799 patients, delayed administration of ticagrelor after fibrinolytic therapy was noninferior to clopidogrel for thrombolysis in myocardial infarction major bleeding at 30 days. However, minor bleeding was increased with ticagrelor and there was no benefit on efficacy outcomes. MeaningBecause most of the included patients were pretreated with clopidogrel, these findings reflect mostly the noninferiority of switching from clopidogrel to ticagrelor in patients already fully loaded with clopidogrel.
JAMA Cardiology – American Medical Association
Published: May 11, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.